Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 6
2004 7
2005 12
2006 8
2007 6
2008 6
2009 7
2010 11
2011 12
2012 7
2013 6
2014 11
2015 14
2016 12
2017 15
2018 9
2019 11
2020 10
2021 13
2022 7
2023 2
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Citations

11 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. Travis WD, et al. Among authors: pelosi g. J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630. J Thorac Oncol. 2015. PMID: 26291008 Free article.
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochem …
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with …
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. Travis WD, et al. Among authors: pelosi g. J Thorac Oncol. 2020 May;15(5):709-740. doi: 10.1016/j.jtho.2020.01.005. Epub 2020 Jan 28. J Thorac Oncol. 2020. PMID: 32004713 Free PMC article. Review.
Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical practice. ...The purpose of this article is to outline detailed recommendations on how …
Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens after neoadjuvant th …
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. Yatabe Y, et al. Among authors: pelosi g. J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18. J Thorac Oncol. 2019. PMID: 30572031 Free PMC article.
Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The International Association for the Study of Lung Cancer Pathology Committee received questions on practical applica …
Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular t …
A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M, Pelosi G, Lopez-Rios F, Kunitoki K, Ferrari-Light D, Sholl LM, Beasley MB, Borczuk A, Botling J, Brambilla E, Chen G, Chou TY, Chung JH, Dacic S, Jain D, Hirsch FR, Hwang D, Lantuejoul S, Lin D, Longshore JW, Motoi N, Noguchi M, Poleri C, Rekhtman N, Tsao MS, Thunnissen E, Travis WD, Yatabe Y, Roden AC, Daigneault JB, Wistuba II, Kerr KM, Pass H, Nicholson AG, Mino-Kenudson M. Moreira AL, et al. Among authors: pelosi g. J Thorac Oncol. 2020 Oct;15(10):1599-1610. doi: 10.1016/j.jtho.2020.06.001. Epub 2020 Jun 17. J Thorac Oncol. 2020. PMID: 32562873 Free PMC article.
INTRODUCTION: A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a set of histologic criteria associated with prognosis aimed at establishing a grading system f …
INTRODUCTION: A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung …
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR. Tsao MS, et al. Among authors: pelosi g. J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22. J Thorac Oncol. 2018. PMID: 29800747 Free PMC article. Clinical Trial.
The goal of BP phase 2 (BP2) was to validate the results obtained in BP phase 1 by using real-world clinical lung cancer samples. METHODS: BP2 were conducted using 81 lung cancer specimens of various histological and sample types, stained with all five …
The goal of BP phase 2 (BP2) was to validate the results obtained in BP phase 1 by using real-world clinical lung cancer sampl …
Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice.
Rossi G, Pelosi G, Barbareschi M, Graziano P, Cavazza A, Papotti M. Rossi G, et al. Among authors: pelosi g. Int J Surg Pathol. 2013 Aug;21(4):326-36. doi: 10.1177/1066896913489346. Epub 2013 Jun 5. Int J Surg Pathol. 2013. PMID: 23740564 Review.
Morphology still remains the cornerstone in lung cancer classification and cytology and small biopsy samples should be interpreted by morphology, whenever feasible, according to shared and widely agreed-upon diagnostic schemes. ...This minimalist 2-hit diagnostic ap …
Morphology still remains the cornerstone in lung cancer classification and cytology and small biopsy samples should be interpr …
Recent advances and current controversies in lung neuroendocrine neoplasms().
Metovic J, Bianchi F, Rossi G, Barella M, Sonzogni A, Harari S, Papotti M, Pelosi G. Metovic J, et al. Among authors: pelosi g. Semin Diagn Pathol. 2021 Sep;38(5):90-97. doi: 10.1053/j.semdp.2021.03.002. Epub 2021 Mar 19. Semin Diagn Pathol. 2021. PMID: 33810912 Review.
Furthermore, a dispute about lung NEN development has been raised according to emerging molecular models. We herein provide a pathology update on practical topics in the setting of lung NENs according to the current classification (recent advances). ...
Furthermore, a dispute about lung NEN development has been raised according to emerging molecular models. We herein provide a patholo …
Morphologic and molecular classification of lung neuroendocrine neoplasms.
Metovic J, Barella M, Bianchi F, Hofman P, Hofman V, Remmelink M, Kern I, Carvalho L, Pattini L, Sonzogni A, Veronesi G, Harari S, Forest F, Papotti M, Pelosi G. Metovic J, et al. Among authors: pelosi g. Virchows Arch. 2021 Jan;478(1):5-19. doi: 10.1007/s00428-020-03015-z. Epub 2021 Jan 21. Virchows Arch. 2021. PMID: 33474631 Free PMC article. Review.
Neuroendocrine neoplasms (NENs) of the lung encompass neuroendocrine tumors (NETs) composed of typical (TC) and atypical (AC) carcinoids and full-fledged carcinomas (NECs) inclusive of large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCLC). ...T …
Neuroendocrine neoplasms (NENs) of the lung encompass neuroendocrine tumors (NETs) composed of typical (TC) and atypical (AC) …
Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications.
Voulaz E, Novellis P, Rossetti F, Solinas M, Rossi S, Alloisio M, Pelosi G, Veronesi G. Voulaz E, et al. Among authors: pelosi g. Expert Rev Anticancer Ther. 2020 Nov;20(11):985-995. doi: 10.1080/14737140.2020.1823223. Epub 2020 Oct 6. Expert Rev Anticancer Ther. 2020. PMID: 32915097 Review.
AREAS COVERED: Rapidly improving imaging technology and genomic analysis has led to a finer discrimination between multiple primary lung tumors and pulmonary metastases. However, over the past few decades, standardized criteria for the identification of multiple lung …
AREAS COVERED: Rapidly improving imaging technology and genomic analysis has led to a finer discrimination between multiple primary lung …
Diagnosis and management of typical and atypical lung carcinoids.
Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Pusceddu S, et al. Among authors: pelosi g. Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Epub 2016 Feb 18. Crit Rev Oncol Hematol. 2016. PMID: 26917456 Review.
According to the 2015 World Health Organization categorization, these tumours are separated into four subtypes characterized by increasing biological aggressiveness: typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma and small-cell carcinoma. Although typi …
According to the 2015 World Health Organization categorization, these tumours are separated into four subtypes characterized by increasing b …
180 results